ATA3431 / Atara, H. Lee Moffitt Cancer Center and Research Institute - LARVOL DELTA

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress (Businesswire) - "...'The Company has made the difficult decision to pause development of its allogeneic CAR-T cell programs and to discontinue all CAR-T operations including terminating the clinical trials evaluating ATA3219'....Atara remains focused on delivering on the future financial value of EBVALLO and has paused ATA3219 and ATA3431 CAR-T programs..."

Discontinued • Hematological Malignancies

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress (Businesswire) - "ATA3219: CD19 Program in Non-Hodgkin’s Lymphoma (NHL): First patient treated in ongoing Phase 1 clinical study of ATA3219 for NHL, including large B-cell lymphomas, follicular lymphoma, and mantle cell lymphoma; Study designed to evaluate safety, preliminary efficacy, pharmacokinetics, and biomarkers; Initial clinical data anticipated in Q1 2025; ATA3431: CD19/CD20 Program for B-Cell Malignancies: Atara is progressing toward an IND submission in Q4 2025."

IND • P1 data • Trial status • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Mantle Cell Lymphoma

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update (Businesswire) - "ATA3219: CD19 Program in Non-Hodgkin’s Lymphoma (NHL) - Atara continues opening sites and initiating enrollment of a multi-center, Phase 1 open-label, dose-escalation clinical trial of ATA3219 in NHL, including large B-cell lymphomas, follicular lymphoma, and mantle cell lymphoma, with initial clinical data anticipated in Q1 2025....ATA3431: CD19/CD20 Program for B-Cell Malignancies:...Atara is progressing toward an IND submission in H2 2025."

IND • P1 data • Trial status • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Mantle Cell Lymphoma

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Businesswire) - "Atara Biotherapeutics, Inc...today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024...ATA3431: CD19/CD20 Program for B-Cell Malignancies...Atara is progressing toward an IND submission in 2025....2024 Outlook and Cash Runway....When combined with certain anticipated payments from Pierre Fabre contingent upon the successful filing and approval of the tab-cel BLA, and operating efficiencies resulting from completed workforce reductions, and the planned transition of substantially all activities relating to tab-cel at the time of the BLA transfer to Pierre Fabre, in total will enable funding of planned operations into 2027."

Financing • IND • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies (TCT-ASTCT-CIBMTR 2024) - "Preclinical evaluations of ATA3431 show B-cell tumor growth inhibition without any treatment-related toxicities and thereby support advancing ATA3431 for clinical evaluation."

IO biomarker • Burkitt Lymphoma • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Oncology • CD20

ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies (ASH 2023) - "Preclinical evaluations of ATA3431 show B-cell tumor growth inhibition without any treatment-related toxicities and thereby support advancing ATA3431 for clinical evaluation. Curran KJ, Sauter CS, Kernan CS, et al. Durable remission following "off-the-shelf" chimeric antigen receptor (CAR) T-cells in patients with relapse/refractory (R/R) B-cell malignancies."

IO biomarker • Burkitt Lymphoma • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD20 • CD22

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting (Businesswire) - "Atara Biotherapeutics...announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies. The data will be presented in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting....ATA3431 demonstrated minimal alloreactivity against HLA mismatched targets due to the inherent ability of EBV T cells to recognize defined viral antigens. The cells also showed HLA-independent activity against CD20+/CD19+ targets in vitro. ATA3431 mediated highly potent tumor growth inhibition in a lymphoma animal model that correlates with long-term persistence without additional exogenous cytokine support."

Preclinical • Lymphoma

Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Businesswire) - "...Initiation of Phase 1 study in relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) for ATA3219—an allogeneic CD19-1XX CAR+ EBV T cell immunotherapy—expected in the coming months with preliminary clinical data anticipated H2 2024....Continued advancement of promising early AlloCAR-T development programs including ATA3431, an allogeneic, bispecific tandem CAR directed against both CD19 and CD20 built on the EBV T-cell platform with a 1XX costimulatory signaling domain. ATA3431 preclinical data has been accepted for poster presentation at the upcoming American Society of Hematology (ASH) meeting in December 2023."

P1 data • Preclinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology